All children and young people with cancer should have the opportunity to take part in relevant clinical trials to increase knowledge about the disease and improve survival rates. This is one of a number of recommendations by the UK’s National Institute for Health and Care Excellence (NICE) to improve standards of care for children, teenagers and young adults with the disease.
The new NICE quality standard for children and young people with cancer says that the participation of the younger generation in clinical trials is “an important factor that has contributed to improved survival rates on childhood cancers.” It calls for suitable trials to be identified by the child or young person’s multidisciplinary care team and that the young child or adult in question is able to make an informed decision about whether or not to participate.
Follows experts’ call for change in EU system
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze